NCT05283057View on ClinicalTrials.gov

Empagliflozin in Patients With Glomerulonephritis

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 20, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
GlomerulonephritisProteinuria
Interventions
DRUG

Empagliflozin 25 MG

single dose of the SGLT inhibitor Empagliflozin was given

DRUG

placebo

single dose of placebo that is similar to Empagliflozin in physical appearance

Trial Locations (1)

Unknown

Cairo university hospitals, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER

NCT05283057 - Empagliflozin in Patients With Glomerulonephritis | Biotech Hunter | Biotech Hunter